Avacta Group transfer technology to BBI Solutions for manufacture of COVID-19 test (Interview)

Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss the appointment of BBI Solutions as manufacturing partner for the COVID-19 test. Alastair talk us through the details, how the prototype is working and the next steps in bringing it to market. Also discussed is the existing agreement with Daewoong Pharmaceutical which has been expanded to include the SARS-CoV-2 neutralising Affimer reagents and the development of the high throughput COVID-19 test with Adeptrix.

Avacta Group also announced that it has entered into a collaboration with the Liverpool School of Tropical Medicine to clinically validate the rapid, saliva-based coronavirus antigen test that Avacta is developing with Cytiva.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Avacta Group Plc

More articles like this

Avacta Group Plc

CORRECTION: Clarification Regarding Medusa 19 Antibody Test

DirectorsTalk would like to highlight that the article from TheBusinessdesk.com has now been deleted and DirectorsTalk would also like to mention that Avacta is not involved in the antibody test produced by Medusa 19. Avacta Group

Avacta Group Plc

More detail on the SARS-CoV-2 ELISA laboratory test

Alastair Smith gives more detail on their latest announcement that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19. Avacta Group Plc

Avacta Group Plc

Avacta signs new deal for Covid-19 testing

Wetherby-based Avacta, in partnership with therapeutic giant Cytiva, is developing a rapid test strip for patient saliva that aims to provide a result in a few minutes, indicating whether the patient is currently infected with the

Avacta Group Plc

Avacta’s partnership with ADC Therapeutics: In detail

On November 1, 2019, Avacta Group and ADC Therapeutics have announced a collaboration agreement for the development of novel drug candidates. What is the objective of the collaboration: The partnership will aim at the development of

Avacta Group Plc

Thanks a billion as LG Chem broadens deal with Avacta

Avacta Group could earn anything from $1/2bn to $1bn from an extended partnership with LG Chem Life Science, the Massachusetts-based subsidiary of the South Korean LG Group. The windfall stems from additional drug development programmes utilising

Avacta Group Plc

Avacta Group and LG Chem Life Sciences expand partnership

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has announced the expansion of its existing multi-target collaboration and development agreement with LG Chem Life Sciences, the life sciences division of the South Korean LG

Avacta Group Plc

BBI appointed to manufacture saliva-based COVID-19 test

South Wales based BBI develops and manufactures raw materials and finished test products for the in-vitro diagnostics market with manufacturing sites in five different countries, spanning four continents. Dr. Mario Gualano, chief executive of BBI Group, said: “BBI are

Avacta Group Plc

Avacta Group Q&A: Demand for coronavirus test to be very high (LON:AVCT)

Avacta Group’s Alistair Smith discusses BBI Solutions as a manufacturing partner, the performance of the prototype with Cytiva, expanding their contract with Daewoong Pharmaceutical and the progress of the COVID-19 test with Adeptrix in this exclusive interview with DirectorsTalk.

Avacta Group Plc

Avacta Group appoints Neil Bell as Chief Development Officer

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has announced the appointment of Neil Bell as Chief Development Officer of Avacta Life Sciences with immediate effect. Neil will be responsible for late stage pre-clinical